The Pharmacological Case for Cannabigerol.

Area of Science:

• Pharmacology
• Cannabinoid Science
• Neuroscience

Background:

• Cannabigerol (CBG) is a precursor to major cannabinoids like Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD).
• Over 100 cannabinoids exist in the cannabis plant, with CBG being a key precursor molecule.
• CBG displays unique interactions with specific receptors, differentiating it from Δ9-THC and CBD.

Purpose of the Study:

• To review the unique pharmacology of CBG.
• To summarize current knowledge on CBG's therapeutic potential.
• To identify potential toxicological hazards associated with CBG.

Main Methods:

• Literature review of existing studies on CBG.
• Analysis of CBG's pharmacological profile, including receptor interactions.
• Evaluation of preclinical and clinical data regarding therapeutic applications and safety.

Main Results:

• CBG shows potential for treating neurologic disorders (e.g., Huntington's, Parkinson's, MS) and inflammatory bowel disease.
• CBG exhibits antibacterial activity.
• CBG interacts uniquely with α-2 adrenoceptors and 5-HT1A receptors.

Conclusions:

• CBG is a promising phytocannabinoid with diverse therapeutic potential.
• Further research is crucial to validate therapeutic claims and assess safety.
• Understanding CBG's pharmacology is essential given its increasing commercialization.